health
February 6, 2026
How AI is helping solve the labor issue in treating rare diseases
At Web Summit Qatar, AI-powered biotech startups describe how automation, data, and gene editing are filling labor gaps in drug discovery and rare disease treatment.
TL;DR
- AI is being used to address the shortage of skilled personnel in drug discovery and gene editing.
- Insilico Medicine utilizes AI for 'pharmaceutical superintelligence,' automating drug discovery tasks from target identification to molecule generation.
- GenEditBio employs AI for in vivo gene editing, using engineered protein delivery vehicles to target specific tissues with precision.
- Both companies highlight the importance of high-quality, diverse data for training AI models to improve accuracy and address biological edge cases.
- The ultimate goal is to increase the number of approved drugs annually and develop personalized treatments for patients.
Continue reading
the original article